Novel 12-LOX Inhibitor Fast Tracked for Heparin-Induced Thrombocytopenia
VLX-1005 is a first-in-class, selective small molecule inhibitor of 12-lipoxygenase, a key target within the arachidonic acid pathway.
Thromboembolic Disorders
Novel Antithrombotic Fast Tracked for Noncardioembolic Ischemic Stroke
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
Xarelto Approved to Treat and Prevent Blood Clots in Pediatric Patients
A new oral suspension formulation of Xarelto has also been approved by the FDA.
FDA Clears Neuromuscular Stimulation Device for Venous Insufficiency and Ischemia
The geko device is designed to stimulate the common peroneal nerve.
High Temperature Exposure Prompts Recall of Anticoagulant Med
Exposure to higher temperatures may have significantly impacted the efficacy of the recalled product.
Rinvoq Labeling Updated to Include Class Warnings Related to JAK Inhibitors
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
FDA Unable to Approve Narsoplimab for HSCT-TMA Without More Data
Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2.
USPSTF: Starting Aspirin in Patients 60 or Older for Primary CVD Prevention Not Recommended
Starting aspirin in patients 60 years or older to prevent a first heart attack or stroke is not recommended.
FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Study Shows Similar Safety Profile With Rivaroxaban vs ASA After Fontan Procedure
The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure.
- Loading...
Loading...
Next post in News
Loading... 
Loading...